论文部分内容阅读
目的探讨阿托伐他汀联合辅酶Q_(10)治疗冠心病早期心功能减退的临床疗效。方法选取乐山市人民医院2014年8月—2016年10月收治的冠心病早期心功能减退患者116例,按照随机数字表法分为对照组和观察组,各58例。对照组患者采用阿托伐他汀片治疗,观察组患者在对照组基础上给予辅酶Q_(10)治疗,两组患者均持续治疗8周。比较两组患者的临床疗效、心功能指标[左心室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)、左心室射血分数(LVEF)],并观察患者不良反应发生情况。结果观察组患者治疗总有效率高于对照组(P<0.05)。观察组患者LVEDD、LVESD低于对照组,LVEF高于对照组(P<0.05)。观察组患者不良反应发生率低于对照组(P<0.05)。结论阿托伐他汀联合辅酶Q_(10)治疗冠心病早期心功能减退的临床疗效确切,可有效改善患者心功能,且安全性高。
Objective To investigate the clinical efficacy of atorvastatin combined with coenzyme Q_ (10) in the treatment of early cardiac dysfunction in patients with coronary heart disease. Methods A total of 116 patients with early hypothyroidism of coronary heart disease admitted from August 2014 to October 2016 in Leshan People’s Hospital were enrolled and divided into control group and observation group according to random number table. Patients in the control group were treated with atorvastatin tablets. Patients in the observation group were treated with coenzyme Q_ (10) on the basis of the control group, and both patients were treated for 8 weeks. The clinical efficacy, cardiac function parameters (LVEDD, LVESD, LVEF) were compared between the two groups. The incidence of adverse reactions was also observed. Results The total effective rate of observation group was higher than that of control group (P <0.05). LVEDD and LVESD in observation group were lower than those in control group, and LVEF was higher in control group (P <0.05). The incidence of adverse reactions in observation group was lower than that in control group (P <0.05). Conclusions Atorvastatin combined with coenzyme Q_ (10) in the treatment of early stage of cardiac dysfunction has the exact clinical curative effect, which can effectively improve the cardiac function of patients with high safety.